Get the Stockscreener App
128.66
6.58%
7.945
Genedx Holdings Corp stock is traded at $128.66, with a volume of 1.68M.
It is up +6.58% in the last 24 hours and up +59.04% over the past month.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
See More
Previous Close:
$120.72
Open:
$121.38
24h Volume:
1.68M
Relative Volume:
1.90
Market Cap:
$3.70B
Revenue:
$267.23M
Net Income/Loss:
$-83.50M
P/E Ratio:
-41.37
EPS:
-3.11
Net Cash Flow:
$-59.99M
1W Performance:
+1.82%
1M Performance:
+59.04%
6M Performance:
+34.26%
1Y Performance:
+278.20%
1-Day Range:
$120.10
$130.33
1-Week Range:
$114.25
$130.33
52-Week Range:
$28.86
$130.33
Genedx Holdings Corp Stock (WGS) Company Profile
Name
Genedx Holdings Corp
Sector
Industry
Phone
888-729-1206
Address
333 LUDLOW STREET, STAMFORD
Compare WGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WGS
Genedx Holdings Corp
|
128.66 | 3.62B | 267.23M | -83.50M | -59.99M | -3.11 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Genedx Holdings Corp Stock (WGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Piper Sandler | Overweight |
| May-15-25 | Initiated | Guggenheim | Buy |
| May-09-25 | Upgrade | Jefferies | Hold → Buy |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-10-24 | Initiated | Craig Hallum | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
View All
Genedx Holdings Corp Stock (WGS) Latest News
GeneDx Holdings Corp. Equity Warrant’s Price Action Aligns with Quant Signals2025 Geopolitical Influence & Capital Efficiency Focused Ideas - beatles.ru
Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action InvestigationWGS - cnhinews.com
Trendlines Suggest GeneDx Holdings Corp. May Bottom Out SoonEarnings Miss & Weekly Top Gainers Alerts - kangso.co.kr
The Unraveling of GeneDx: Securities Litigation and the Erosion of Shareholder Value - AInvest
Will GeneDx (WGS) Navigate Management Credibility Challenges After Securities Investigation News? - simplywall.st
Can GeneDx Holdings Corp. Equity Warrant outperform in the next rallyShort Setup & Precise Buy Zone Identification - mustnews.co.kr
Watch for Trend Continuation in GeneDx Holdings Corp. Next Week2025 Earnings Impact & Real-Time Volume Triggers - newsyoung.net
Can GeneDx Holdings Corp. Rally Enough to Break Even2025 Investor Takeaways & Smart Allocation Stock Tips - sundaytimes.kr
WGS Investor News: If You Have Suffered Losses in GeneDx - GlobeNewswire
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are - Bluefield Daily Telegraph
Genedx Holdings Corp. shares fall 2.20% intraday after Rosen Law Firm investigates potential securities claims. - AInvest
GeneDx Holdings Corp. Stock Lags Behind Sector BenchmarksJuly 2025 Setups & Daily Profit Maximizing Trade Tips - sundaytimes.kr
GeneDx Holdings Corp. Securities Class Action Investigation - AInvest
GeneDx Holdings stock hits 52-week high at 118.47 USD By Investing.com - Investing.com South Africa
GeneDx Holdings stock hits 52-week high at 118.47 USD - Investing.com
GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ROSEN, LEADING TRIAL ATTORNEYS, Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action InvestigationWGS - ACCESS Newswire
GeneDx at Canaccord Conference: Expanding Genomic Horizons By Investing.com - Investing.com Nigeria
GeneDx at Canaccord Conference: Expanding Genomic Horizons - Investing.com
How Investors May Respond To GeneDx Holdings (WGS) Raising 2024 Revenue Guidance After Swing to Profit - simplywall.st
GeneDx Holdings Corp. (WGS) Sees Solid Earnings Growth Amid Rising Estimates - AInvest
Will GENEDX HOLDINGS (WGS) Gain on Rising Earnings Estimates? - Yahoo Finance
WGS Investor News: If You Have Suffered Losses in GeneDx Holdings Corp. (NASDAQ: WGS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Genedx Holdings Corp. shares rise 1.90% after-hours as Rosen Law Firm investigates potential securities claims. - AInvest
Should You Buy GeneDx Holdings Corp. (WGS) After Golden Cross? - Zacks Investment Research
Industry Analysts Just Upgraded Their GeneDx Holdings Corp. (NASDAQ:WGS) Revenue Forecasts By 11% - 富途牛牛
GeneDx Holdings' (NASDAQ:WGS) Performance Is Even Better Than Its Earnings Suggest - Yahoo Finance
GENEDX (WGS) ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
William Blair Investment Management, LLC's Strategic Acquisition in GeneDx Holdings Corp - GuruFocus
GeneDx investigated for misleading statements and practices. - AInvest
Scott+Scott Attorneys at Law LLP Alerts Investors to Its Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS) - GlobeNewswire
GeneDx Leadership to Present at 3 Premier Healthcare Conferences: Morgan Stanley, Wells Fargo, Canaccord - Stock Titan
GeneDx to Participate in Upcoming Investor Conferences - Business Wire
Piper Sandler reiterates Overweight rating on GeneDx stock, citing multiyear growth potential - Investing.com Canada
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication - ADVFN Brasil
Genedx Holdings Corp. shares rise 1.59% intraday after Rosen Law Firm investigates potential securities claims. - AInvest
How does GeneDx Holdings Corp. generate profit in a changing economyCapitalize on market momentum for big wins - Jammu Links News
What catalysts could drive GeneDx Holdings Corp. stock higher in 2025Maximize gains with expert analysis - Jammu Links News
Published on: 2025-08-04 06:03:13 - Jammu Links News
Is GeneDx Holdings Corp. stock overvalued or undervaluedHigh-margin investment plays - Jammu Links News
Published on: 2025-08-04 04:10:50 - Jammu Links News
What are analysts’ price targets for GeneDx Holdings Corp. Equity Warrant in the next 12 monthsTremendous gains - Jammu Links News
How many analysts rate GeneDx Holdings Corp. Equity Warrant as a “Buy”Discover high-growth stocks for your portfolio - Jammu Links News
Should I hold or sell GeneDx Holdings Corp. Equity Warrant stock in 2025Achieve rapid capital gains with smart investing - Jammu Links News
How volatile is GeneDx Holdings Corp. stock compared to the marketInvest with confidence backed by data - Jammu Links News
Is GeneDx Holdings Corp. Equity Warrant stock overvalued or undervaluedBuild a diversified portfolio for risk mitigation - Jammu Links News
How strong is GeneDx Holdings Corp. company’s balance sheetGet timely market insights for better trades - Jammu Links News
What institutional investors are buying GeneDx Holdings Corp. stockFree Daily Trading Room Entry - Jammu Links News
How strong is GeneDx Holdings Corp. Equity Warrant company’s balance sheetBuild your wealth with consistent stock growth - Jammu Links News
When is GeneDx Holdings Corp. Equity Warrant stock expected to show significant growthAchieve rapid returns with smart investment plans - Jammu Links News
What analysts say about GeneDx Holdings Corp. Equity Warrant stockSignificant capital appreciation - Jammu Links News
Genedx Holdings Corp Stock (WGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Genedx Holdings Corp Stock (WGS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jul 29 '25 |
Sale |
105.31 |
388 |
40,860 |
3,757 |
| Stueland Katherine | Chief Executive Officer |
Jul 29 '25 |
Option Exercise |
0.00 |
3,874 |
0 |
5,594 |
| Stueland Katherine | Chief Executive Officer |
Jul 29 '25 |
Sale |
105.31 |
2,154 |
226,838 |
3,440 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jul 09 '25 |
Option Exercise |
32.67 |
1,245 |
40,674 |
8,670 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jul 09 '25 |
Sale |
93.00 |
5,278 |
490,854 |
3,392 |
| Stueland Katherine | Chief Executive Officer |
Jul 09 '25 |
Sale |
93.00 |
3,220 |
299,460 |
1,720 |
| Stueland Katherine | Chief Executive Officer |
Jul 01 '25 |
Sale |
90.94 |
9,657 |
878,181 |
4,940 |
| Feeley Kevin | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Sale |
91.12 |
1,344 |
122,471 |
7,425 |
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):